A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety profile and tolerability of
single oral doses of daclatasvir in subjects with chronic hepatitis C infection